H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...
H.C. Wainwright launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and $6 price target. The stock closed at $2.04 on Dec. 9. Affimed is a clinical-stage biotechnology company focused on developing innate...
H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies (NASDAQ:IPA) with a “buy” rating and price target of $9. The stock closed at $4.93 on Dec. 1. ImmunoPrecise is a contract research organization (CRO) that...
H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...
H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...
H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...
H.C. Wainwright initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and 12-month price target of $25. The stock closed at $8.02 on Dec. 9. Delcath is a clinical-stage interventional oncology company...
H.C. Wainwright downgraded Sesen Bio (NASDAQ:SESN) to “neutral” from “buy” and removed its price target after the company on Aug. 13 received a complete response letter from the FDA. The stock closed at $2.11 on Aug. 13...
H.C. Wainwright launched coverage of Asensus Surgical (NYSE American:ASXC) with a “buy” rating and price target of $4. The stock closed at $2.03 on May 25. Asensus, a surgical robotics company, is digitizing laparoscopy...
H.C. Wainwright launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with a “buy” rating and $37 price target. The stock finished at $23.03 on May 4. ITeos Therapeutics, which is developing next-generation immuno...